Erbb2 DNA vaccine combined with Treg cell deletion enhances antibody response and reveals
latent low-avidity T cells. Potential and limits of its therapeutic efficacy
Simona Rolla*§, Francesco Ria†§, Sergio Occhipinti*, Gabriele Di Sante†, Manuela Iezzi‡, Michela
Spadaro*, Chiara Nicolò†, Elena Ambrosino*, Irene Fiore Merighi*, Piero Musiani‡, Guido Forni*
af
te
r
us
e.
and Federica Cavallo*¶
oy
*Molecular Biotechnology Center, Department of Clinical and Biological Sciences, University of
es
Aging Research Center (CeSI), G. d’Annunzio University Foundation, 66013 Chieti, Italy.
Address correspondence to Federica Cavallo, Department of Clinical and Biological Sciences,
td
¶
equally contributed
is
t
§
rib
ut
e.
‡
Institute of General Pathology, Catholic University Sacro Cuore, 00168 Rome, Italy.
D
†
tr
Torino,10126 Turin, Italy.
no
Molecular Biotechnology Center , 10126 Torino, Italy, Phone: +39 011 670 6454; Fax: +39 011
ew
.D
o
236 5417, E-mail:
[email protected]
ev
i
Running title: Treg deletion and DNA vaccination against Erbb2 carcinomas
Fo
rP
ee
r
R
Key Words: Erbb2, DNA vaccination, Treg cells, TCR repertoire
1
Abstract
Rat (r) Erbb2 transgenic BALB-neuT mice genetically predestined to develop multiple
invasive carcinomas allow an assessment of the potential of a vaccine against the stages of cancer
progression. Due to Erbb2 expression in the thymus and its over-expression in the mammary gland,
e.
CD8+ T cell clones reacting at high avidity with dominant Erbb2 epitopes are deleted in these mice.
us
In BALB-neuT mice with diffuse and invasive in situ lesions and almost palpable carcinomas, a
temporary Treg cells depletion combined with anti-rErbb2 vaccine markedly enhanced the anti-
te
r
rErbb2 antibody response and allowed the expansion of latent pools of low-avidity CD8+ T cells
af
bearing T cell receptors repertoire reacting with the rErbb2 dominant peptide. This combination of
oy
a higher antibody response and activation of a low-avidity cytotoxic response persistently blocked
es
tr
tumor progression at stages in which the vaccine alone was ineffective. However, when diffuse and
D
invasive microscopic cancers become almost palpable this combination was no longer able to
Fo
rP
ee
r
R
ev
i
ew
.D
o
no
td
is
t
rib
ut
e.
secure a significant extension of mice survival.
2
Introduction
The consistent step-wise progression of tumors arising in tumor-prone genetically
engineered mice allows the assessment of the ability of a vaccine to both provide protection
e.
against progressive stages of neoplasia and to elicit a response from an immune system
us
negatively imprinted by the slow expansion of an autochthonous tumor. In these cancer models,
natural life span, but is usually unable to cure advanced microscopic lesions (1).
te
r
vaccination can significantly prevent neoplastic progression for nearly as long as a mouse’s
af
This loss of efficacy is due to a tumor’s increasing ability to augment its mitotic activity,
oy
clonal diversification, and inaccessibility to the mechanisms of the immune reaction. However,
es
tr
the efficacy of a vaccine administered to mice bearing diffuse microscopic lesions is also
D
diminished by the tumor-driven expansion of various kinds of negative regulatory cells (1).
e.
Numerous experiments show that this expansion results in both a far less significant immune
ut
response, and suppression of its effector arm (2-9).
rib
Tumor-driven regulatory cells expansion also changes the tumor-specific T cell repertoire
is
t
(5, 10) due to both direct contacts and the production of soluble factors such as TGF-β or IL-10.
td
In a special way, T regulatory (Treg) cells may inhibit the reaction of low avidity T cells against
no
tumor antigens (10).
.D
o
This study assesses the significance of Treg cell expansion in the inefficacy of vaccination
against different stages of tumor progression in female BALB/c mice transgenic for the
ew
transforming rat (r) Erbb2/neu (rErbb2) oncogene (BALB-neuT mice) (11) that develop invasive
ev
i
and metastatic mammary cancer (12). We have previously shown that expression of the rErbb2
R
protein product (Erbb2) in their thymus and mammary glands has a dramatic impact on the
ee
r
repertoire of CD8+ T cells that reach the periphery. By contrast with wild-type BALB/c mice,
rP
anti-rErbb2 immunization does not elicit a detectable cytotoxic response in BALB-neuT mice
Fo
(13, 14). Since they are devoid of the CD8+ T cell clones that react in the wild-type with high
avidity against the immunodominant rErbb2 peptide (15), their anti-tumor reactivity is mostly
confined to CD4+ T cells and antibody production (15-17).
Hyperplastic foci appear from the 4th week of age in all mammary glands of BALB-neuT
mice, expand to multiple areas of atypical hyperplasia and give rise to disseminated tumor cells
and micrometastasis in bone marrow and lungs (10th week), and progress to in situ carcinomas
(14th week), which expand and merge to give rise to carcinomas that are initially microscopic
(16th week), then become diffuse and invasive (18th week) and almost palpable around the 20th
3
week (12, 18). This progression is accompanied by rampant immune suppression. Expansion of
Treg cells (19), and immature myeloid cells (20) along with NKT cells (21) progressively inhibits
natural immune surveillance. We have shown that chronic infusion of anti-CD25 Ig results in a
sustained depletion of Treg cells, greatly delays carcinogenesis and unveils a natural immune
response to rErbb2 (19).
Here we set out to determine whether anti-rErbb2 DNA vaccination combined with
us
e.
temporary Treg cell deletion provides better protection against stages of mammary lesions whose
progression can no longer be inhibited by vaccination alone. In BALB-neuT mice harbouring
te
r
microscopic in situ lesions and almost palpable carcinomas, this combination markedly enhanced
af
the anti-rErbb2 antibody response, and allowed both the expansion of latent pools of low-avidity
oy
CD8+ T cells bearing T cell receptor (TCR) repertoires reacting with the rErbb2 dominant
tr
peptide, and their activation against this peptide. The result was a persistent blockade of tumor
D
es
progression at stages in which the vaccine alone was ineffective, whereas survival of mice with
Fo
rP
ee
r
R
ev
i
ew
.D
o
no
td
is
t
rib
ut
e.
diffuse, invasive and almost palpable microscopic lesions was not significantly extended.
4
Materials and methods
Mice
Severe combined immunodeficient (SCID) mice, wild type BALB/c mice and BALB-neuT 6-weekold female mice were from Charles River Italia SpA (Calco, Italy). BALB-neuT mice overexpress
the rErbb2 transforming oncogene under the control of the mouse mammary tumor virus promoter
us
e.
and develop a multifocal and metastatic carcinoma in each of their ten mammary glands with a
stepwise progression (12, 18). BALB-neuT mice unable to produce antibodies (BALB-neuT/BKO
te
r
mice) were generated by crossing BALB-neuT mice with BALB/c mice knocked out for the Ig µ
af
chain gene (17). Mice were randomly assigned to control and treatment groups and all groups were
oy
treated concurrently. Mammary glands were inspected weekly to note tumor appearance.
tr
Neoplastic masses were then measured with calipers in two perpendicular diameters and the
es
average value recorded. Progressively growing masses >1 mm mean diameter were regarded as
e.
D
tumors. Tumor volume was calculated as (X2 x Y) / 2, where X and Y represent the short and long
ut
diameters, respectively. Total tumor volume is the sum of individual tumor volumes of each mouse
rib
and is reported as mean ± SD. Tumor multiplicity was calculated as the cumulative number of
is
t
incident tumors/total number of mice at the time of death. Values are reported as mean ± SEM.
td
Mammary whole mount preparations were performed as previously reported (19). According to our
no
ethical protocol mice were killed when a first tumor exceeded 10 mm mean diameter. All the
.D
o
experiments were approved by the institutional Ethical Committee and mice were treated in
ew
accordance to the European Union guidelines.
ev
i
Production and administration of anti-CD25 Ig.
R
The PC61 hybridoma-secreting IgG1 monoclonal antibody to the alpha-chain of murine IL-2
ee
r
receptor (CD25) was purchased from the American Type Culture Collection (Manassas, VA) and
cultured in DMEM (Sigma-Aldrich, St. Louis, MO) supplemented with 5% fetal bovine serum
rP
(FBS, Life Technologies, Milan, Italy), 0.5 mmol/l sodium pyruvate,1 mmol/l nonessential amino
Fo
acid, 1.25 g/l bicarbonate, and 25.7 mmol/l h-mercaptoethanol and then grown as ascites in SCID
mice. The titer of IgG1 in the ascite fluids passed through 0.45 Am membrane filters (BD
Biosciences, Erembodegem, Belgium) was determined with radial immunodiffusion kits (The
Binding Site Ltd., Birmingham, United Kingdom). The fluid was diluted in phosphate buffered
saline (PBS, Sigma-Aldrich) to obtain a concentration of 2.5 mg/ml as previously described in
details (19). At the specified times BALB-neuT mice received 0.5 mg of anti-CD25 or rat IgG1
isotype control (eBioscience, San Diego, CA) injected intra peritoneum.
5
Cytometric identification of Treg cells.
The relative numbers of CD4+ CD25+ GITR+ FoxP3+ Treg in the lymph nodes (LN) draining the
mammary pad were evaluated by flow cytometry. One x 106 cells were treated with Fc receptor
blocker (CD16/CD32; PharMingen, San Diego, CA) for 15 minutes at 4°C. Directly conjugated
phycoerythrin (PE) anti-mouse GITR (clone DTA-1, eBioscience), PE/Cy7 anti-mouse CD4 (clone
us
e.
GK1.5, BioLegend, San Diego, CA), and allophycocyanin (APC) anti-mouse CD25 (clone PC61.5,
eBioscience) were incubated for 30 minutes at 4°C. The cells were then washed in PBS (Sigma-
te
r
Aldrich) with 0.1% sodium azide and 2% bovine serum albumin (BSA, Sigma-Aldrich)(PBS-azide-
af
BSA). Cell pellets were suspended in 1 ml Fix/Perm (eBioscience) and the samples were incubated
oy
overnight at 4°C. After two washes with permeabilization buffer (eBioscience), the samples were
tr
incubated with 2 µl Fc receptor blocker for 15 minutes at 4°C and then with FITC anti-mouse/rat
D
es
FoxP3 (FJK-16s, eBioscience) for 30 minutes at 4°C. The samples were washed twice with PBS-
e.
azide-BSA and analyzed on the CyAn ADP (DakoCytomation, Glostrup, Denmark) through
rib
ut
Summit 4.2 (DakoCytomation) software.
is
t
Preparation of DNA plasmids and DNA electroporation
td
The pcDNA3 vector coding the extracellular and transmembrane domains of the rErbb2 (EC-TM
no
plasmid) was produced and used as previously described (22) with slight modifications. Fifty µg of
.D
o
EC-TM or empty pcDNA3 plasmid in 20 µl sterile water with 0.9% NaCl were injected into the
quadriceps muscle of anesthetized mice. Immediately after, two electrical pulses of 375 V/cm of 25
ew
milliseconds in duration were applied using CliniporatorTM device and linear needle electrodes
ev
i
(Igea, Carpi, Italy) inserted in the muscle. Each electroporation course consisted of two plasmid
ee
r
R
administrations with an interval of 14 days.
Immunohistochemistry and histology of the mammary glands.
rP
For immunohistochemistry, six–micron cryostat section were air- dried and fixed in ice-cold
Fo
acetone for 10 min. Slides were incubated with anti-CD8 primary antibody (Abcam - Cambridge,
UK) and than with the biotinylated secondary antibody. Immunoreactive antigens were detected
using NeutrAvidinTM Alkaline Phosphatase Conjugated (Thermo Scientific-Pierce Biotechnology,
Rockford, USA) and Vulcan Fast Red (Biocare Medical, Concord, CA) or DAB Chromogen
System (Dako Corporation , Carpinteria, CA - USA). For histologic evaluation, tissue samples were
fixed in 10% neutral-buffered formalin, embedded in paraffin, sectioned at 4 μm, and stained with
H&E. Tumor vessel were analized by Immunofluorescence with anti-CD31 (marker of endothelial
6
cells) ( BD Pharmingen), -NG2 (marker of nascent pericytes) (Chemicon, Temecula, CA) and αSMA (marker of mature pericytes) (Sigma).
Antibody response
Sera from mice of each treatment group were diluted 1:100 in PBS-azide-BSA. The presence of
antibodies against rErbb2 was determined by flow cytometry using BALB/c 3T3 fibroblasts wild-
us
e.
type or stably co-transfected with rErbb2, mouse class I H-2Kd and B7.1 genes (BALB/c 3T3-NKB)
(23). These cells were cultured in DMEM supplemented with 20% FBS at 37° C in a humidified
te
r
5% CO2 atmosphere. FITC-conjugated goat anti-mouse antibodies specific for mouse IgG Fc
af
(DakoCytomation) were used to detect bound primary antibodies. Normal mouse serum was used
oy
as negative control. The monoclonal antibody Ab4 (Oncogene Research Products, Cambridge,
es
tr
MA), which recognizes an extracellular domain of rErbb2 was used as a positive control. After
D
washing, cells were suspended in PBS-azide-BSA containing 1 mg/ml of propidium iodide to
e.
exclude dead cells and evaluated in a CyAn ADP (DakoCytomation). The results are expressed as
ut
3T3-NKB specific binding potential calculated as follows: [(% positive cells with test
is
t
no
Cytotoxic T lymphocyte assays
td
dilution as previously described in detail (24).
rib
serum)(fluorescence mean)] – [(% positive cells with control serum) (fluorescence mean)] x serum
.D
o
To prepare target cells for in vivo cytotoxicity detection (25), erythrocytes in BALB/c spleen cell
suspension (SPC) were removed by osmotic lyses. Cells were then washed and split into two target
ew
populations. One was labelled with 5 μM carboxyfluorescein succinimidyl ester (CFSE, Molecular
ev
i
Probes, Invitrogen, Carlsbad, CA), then pulsed with the dominant 63-71 rErbb2 peptide (p63-71,
R
TYVPANASL, INBIOS Srl, Naples, Italy) with H-2Kd restriction element (26) at a concentration of
ee
r
3 or 15 μg/ml for 1 h at 37° C (CFSEhigh cells). The control SPC were left without peptides and
rP
labelled with 0.5 μM CFSE (CFSElow cells). For injection, an equal number of SPC from each
population were mixed together. Recipient mice were injected intravenously with 20 x 106 cells
Fo
suspended in 0.3 ml of PBS. Mice were bled 18 hours later and peripheral blood mononuclear cells
were analyzed using flow cytometry as we previously described (19). To detect IFNγ production
lymphocytes from LN or SPC were cultured in presence of 3, 15 or 50 μg/ml of the p63-71 for 18
hour plus 10 μg/ml Brefeldin A (Sigma-Aldrich) for the last five hours. Cells were stained with
anti-mouse APC CD8 (PharMingen) and then fixed, permeabilized and stained intracellulary with
anti-mouse PE IFNγ (eBioscience).
7
T cell repertoire analysis.
Repertoire analysis was performed as previously described in detail (15). Popliteal and inguinal LN
cells were collected from the various groups of mice and 5 x 106/ml cells were cultured for 3 days
in the presence of 3, 15, or 50 µg/ml of p63-71 or mitomycin-C (Sigma-Aldrich) treated 3T3-NKB
cells. Culture medium was RPMI 1640 (Gibco Basel, Switzerland), supplemented with 2mM L-
us
was isolated from CD4+ and CD8+ immunobeads sorted cells (15) with the RNeasy Mini Kit
e.
glutamine, 50 µM 2-ME, 50 µg/ml gentamicin (all from Sigma-Aldrich) and 10% FBS. Total RNA
(Qiagen, Hilden, Germany) according to the manufacturer's instructions. cDNA synthesized using
te
r
an oligo-dT primer (dT15) (Invitrogen) was subjected to PCR amplification using a common Cβ
af
primer in combination with the various Vβ primers as previously described in details (15). Using 2
oy
μl of PCR product as a template, run-off reactions were performed with the internal fluorescent Jβ
es
tr
primers (15, 27). The run-off products were denatured in formamide and analyzed on an Applied
D
Biosystem 3100 Prism using Gene-scan 2.0 software (Applied Biosystem, Foster City, CA). Results
rib
ut
with antigen/normalized peak area of non-stimulated cells).
e.
are reported as rate stimulation index (RSI = normalized peak area obtained from cells stimulated
is
t
CD8 depletion.
td
For CD8+ T cell depletion, BALB-neuT mice were injected with 50 µg of anti-mouse CD8 mAb
no
(Cederlane, Ontario, Canada) every 10 ten days starting the day before the first vaccination. Three
.D
o
weeks later mice were challenged sub coutaneously with 1x105 TUBO cells, a ErbB2+ cloned cell
ew
line established in vitro from a lobular carcinoma that arose in a female BALB-neuT mouse (13).
ev
i
Statistics
R
Differences in data were evaluated with the two-tailed Student’s t test, except that differences in
Fo
rP
ee
r
tumor incidence were evaluated with the Mantel-Haenszel log-rank test (11).
8
Results
Anti-CD25 Ig persistently impairs Treg expansion during rErbb2 carcinogenesis. At the 10th week
of age BALB-neuT mice display atypical hyperplasia foci scattered in all ten mammary glands (18)
and disseminated tumor cells and micrometastasis in bone marrow and lungs (12). Progression of
these lesions to in situ and invasive cancer is accompanied by the expansion of CD4+ CD25+ GITR+
us
e.
FoxP3+ Treg cells (19). To examine the effect of anti-CD25 Ig on Treg cells in tumor draining LN,
10-week-old BALB-neuT mice received two injections of control or anti-CD25 Ig four days apart.
te
r
While a progressive expansion of CD4+ CD25+ GITR+ FoxP3+ cells was evident in mice receiving
es
tr
oy
remained significantly lower than in control mice until about week 30 (Fig. 1).
af
control Ig, two weeks after the injections of anti-CD25 Ig their number fell dramatically and
D
Anti-CD25 Ig delays cancer progression and enhances the anti-tumor protection afforded by EC-
e.
TM plasmid electroporation. While the two injections of anti-CD25 Ig alone at week 10 were
ut
enough to elicit a small, but significant delay in the appearance of mammary tumors, all the treated
rib
BALB-neuT mice displayed at least one palpable tumor by week 27 (Fig. 2A). EC-TM plasmid
is
t
electroporation at week 10 and 12 almost doubled the tumor-free survival, but all mice were dead at
td
week 65. When the first electroporation of EC-TM plasmid was combined with anti-CD25 Ig one
no
and four days later, tumor free survival exceeded one year (Fig. 2A), and 44% of mice were still
.D
o
alive at 100 weeks of age, when the experiment ended, and those that developed tumors displayed a
ew
lower multiplicity (supplementary Table I).
ev
i
Immune mechanisms enhanced by the combination of anti-CD25 Ig and EC-TM plasmid
electroporation. The antibody response to rErbb2 and the cytotoxic response in vivo against the
ee
r
R
immunodominant H-2Kd p63-71 (26) were evaluated at progressive times after both the two antiCD25 Ig injections and EC-TM plasmid electroporation. The two injections at week 10 elicited a
rP
small but significant antibody response (Fig. 2B) and a marked cytotoxic response (Fig. 2C). Both
Fo
responses were evident four and ten weeks later and then faded. A significant and persistent
antibody response but a marginal cytotoxicity followed EC-TM plasmid electroporation. However,
the combination of EC-TM plasmid electroporation and anti-CD25 Ig injection resulted in both a
stronger antibody response and a marked and persistent cytotoxic response (Fig. 2B and C).
Anti-CD25 Ig administration unveils CD8+ T cells participating in tumor halting.
9
A marked cytotoxic response to rErbb2 following anti-CD25 Ig administration, alone or in
combination with EC-TM plasmid electroporation, was a new and unexpected finding, since it had
never been found in BALB-neuT mice when different protocols of immunizations were adopted (1,
13, 22, 28). Indeed, BALB-neuT mice lack the CD8+ T cells reacting with high avidity with the
rErbb2 immunodominant p63-71 (15). To look for the mechanisms whereby Treg cell depletion
allows anti-rErbb2 vaccination to elicit such a response, we evaluated the p63-71 specific T cell
us
e.
repertoire thus expanded. Wild type BALB/c mice and BALB-neuT mice were electroporated at
week 10 and 12 with EC-TM plasmid. A few of them, together with untreated mice, received anti-
te
r
CD25 Ig one and four days after the first electroporation. At week 14, popliteal and inguinal LN
af
cells were collected and cultured with the p63-71. The 288 Vβ-Jβ primer combinations were used to
oy
perform the first CDR3 length fragment analysis on a pool of cDNA from five treated BALB-neuT
es
tr
mice. After in vitro re-stimulation with p63-71, antigen-driven perturbation of normal CDR3-β
D
profile was observed in 8 spectra from this pool (Fig. 3A). These rearrangements were then
e.
checked in other 10 (individual) mice. Three groups of rearrangements specific for the p63-71 were
ut
shared among sorted CD8+ T cells from treated mice: Vβ1-Jβ1.1 of 137 bp length (used by 4/10
rib
mice), Vβ6-Jβ2.7 of 109 or 115 bp length (each used by 6/10 mice), and Vβ7-Jβ1.2 of 134 or 137
is
t
bp length (used by 3/10 and 4/10 mice, respectively) (Fig.3B). Vβ9-Jβ1.2 rearrangements (98 and
td
104 bp length) specific for p63-71, used by the vast majority of BALB/c mice electroporated with
no
or without anti-CD25 Ig were never expanded in any of the BALB-neuT mice (Table I), in keeping
.D
o
with our previous finding (15). These data hint that the p63-71 specific repertoire expanded
following Treg cell depletion in BALB-neuT mice does not overlap with that activated by EC-TM
ew
plasmid electroporation in BALB/c mice, whether alone or in combination with anti-CD25 Ig. To
ev
i
find evidence of this difference, we tested the usage of Vβ1-Jβ1.1, Vβ6-Jβ2.7, Vβ7-Jβ1.2 and Vβ9-
R
Jβ1.2 in BALB/c and BALB-neuT mice electroporated with EC-TM plasmid at week 10 and 12
ee
r
only, injected twice with anti-CD25 Ig at week 10 only, or electroporated and injected. Irrespective
rP
of the administration or not of anti-CD25 Ig, all the electroporated BALB/c mice expanded the
Fo
Vβ9-Jβ1.2 rearrangements, whereas it was not used by any BALB-neuT mouse (Table I).
Somewhat surprisingly, anti-CD25 Ig administration alone led to the expansion of Vβ1-Jβ1.1, Vβ6Jβ2.7, and Vβ7-Jβ1.2 rearrangements in a limited but substantial number of BALB-neuT mice.
These rearrangements are also expanded in most of BALB-neuT mice receiving the EC-TM
plasmid electroporation plus anti-CD25 Ig administration.
10
Features of p63-71 specific T cells in BALB-neuT mice. The cytotoxic response elicited in vivo by
the combined treatment is of lower avidity than that induced in BALB/c mice electroporated with
EC-TM only. Marked cytotoxic activity in vivo is evident against target cells only when these are
pulsed with 15 µM but not 3 µM p63-71 (Fig. 4A). The cytotoxic response is parallel to a sustained
CD8+ T cell infiltration of mammary lesions in mice receiving the combined treatment (Fig 4B).
Accordingly, TCR repertoire analysis shows that CD8+ cells expressing the Vβ1-Jβ1.1 and Vβ7-
us
e.
Jβ1.2 rearrangements infiltrate tumor lesions (Fig 5A).
In vitro, too, the T cell response elicited by the combined treatment is of a relatively low-avidity.
te
r
While a significant number of CD8+ T cells from EC-TM electroporated BALB/c mice is induced
af
to produce IFNγ by 3 μM p63-71, 15 μM p63-71 is required to trigger CD8+ IFNγ secreting cells
oy
(Fig 5A) from BALB-neuT mice receiving the combined treatment. Furthermore, the number of
es
tr
IFNγ−producing T cells in these mice is also consistently lower than that in BALB/c mice (Fig.5),
D
even under optimal concentration of stimulating antigen. The CD8+ cells carrying the shared
e.
rearrangements differ in their ability to expand in vitro in response to p63-71 (Fig. 5B). Those
ut
carrying the Vβ9-Jβ1.2 rearrangements used by EC-TM electroporated BALB/c mice expand
rib
significantly already at a concentration of 3 μM p63-71; of the riarrangements used by BALB-neuT
is
t
mice receiving the combined treatment, Vβ7-Jβ1.2 alone displays a marginal ability to expand in
td
the presence of 3 μM p63-71. At the optimal concentration of 15 μM p63-71, all the three CD8-
no
associated rearrangements expanded, but with a lower proliferative capacity than the Vβ9-Jβ1.2
.D
o
cells, as indicated by the lower RSI (Fig. 5B). Though not a direct measurement, the sensitivity ot
ew
antigen stimulation in vitro has been shown to reflect the antigen avidity of a T cell (29). Thus,
taken together these results suggest that the CD8+ cells activated in BALB/c mice constitute a
ev
i
repertoire characterized by high antigen avidity, whereas the CD8+ cells recruited in BALB-neuT
R
mice behaves as a repertoire characterized by lower avidity.
ee
r
Lastly, the combined treatment is still able to elicit a reaction which impairs the progression of
rP
Erbb2 lesions in BALB-neuT/BKO mice unable to produce antibodies (Fig. 4C). In the same way,
Fo
depletion of CD8+ cells reduces its ability to protect BALB-neuT mice from a subsequent tumor
challenge (Supplementary Table II).
Anti-CD25 Ig administration expands, but does not change CD4+ T cell repertoires
We have previously shown that BALB-neuT mice expand CD4+ lymphocytes expressing the Vβ11Jβ2.7 and the Vβ13-Jβ2.3 rearrangements following EC-TM electroporation, whereas BALB/c
11
mice expand CD4+ cells with different TCR rearrangements (15). To determine whether EC-TM
plasmid electroporation plus anti-CD25 Ig also affects the CD4+ T cell repertoire, LN cells from
BALB/c and BALB-neuT mice electroporated with or without anti-CD25 Ig were cultured with
rErbb2+ BALB/c 3T3-NKB cells (23). Expansion of the Vβ11-Jβ2.7 and the Vβ13-Jβ2.3
rearrangements was observed following EC-TM plasmid electroporation with or without anti-CD25
Ig administration (Table I). Administration of anti-CD25 alone led to the expansion of lymphocytes
us
e.
expressing the Vβ11-Jβ2.7 and the Vβ13-Jβ2.3 rearrangements in a significant number of BALB-
neuT mice. These results suggest that CD4+ T cells expressing a public TCR repertoire specific for
te
r
rErbb2 are naturally present in the periphery of BALB-neuT mice and can be expanded either by
af
active immunization or by Treg cell depletion alone. These rearrangements were not expanded in
oy
BALB/c mice receiving anti-CD25 Ig alone or in combination with EC-TM plasmid
D
es
tr
electroporation.
e.
Anti-CD25 Ig administration enables EC-TM plasmid electroporation to cure diffuse and invasive
ut
microscopic Erbb2 carcinomas.
rib
To determine whether combination with anti-CD25 Ig improves the therapeutic efficacy of EC-TM
is
t
plasmid, BALB-neuT mice received two courses of EC-TM plasmid electroporation, alone or
td
combined with anti-CD25 Ig, at different stages of mammary cancer progression. Since Treg cells
no
rapidly expand as a tumor grows, anti-CD25 Ig was injected 14 and 10 days before the first
.D
o
electroporation to remove most of them. At week 16, when multiple in situ carcinomas formed of
clusters of tumor cells separated by bands of delicate stroma rich in blood vessels are scattered in all
ew
mammary glands (Supplementary Fig. S1), EC-TM plasmid electroporations alone still elicited a
ev
i
significant anti-rErbb2 antibody response but not a cytotoxic response, and the influence of this
R
reaction on survival was still significant (Supplementary Fig. S1). Combination of anti-CD25 Ig
ee
r
led to a stronger antibody response, triggered a significant cytotoxic response to the dominant p63-
rP
71 (Fig. 6), reduced tumor multiplicity (Supplementary Table) and kept 36% of mice free of
Fo
palpable tumors at week 100 when the experiment ended (Fig. 6).
At week 18, the clusters coalesce to form masses that invade mammary glands (Fig. 6)
and are surrounded by a dense stroma with large vessels (Supplementary Fig. S1). Once again, ECTM plasmid electroporation alone elicited a significant antibody response, but its influence on
survival was marginal (Supplementary Fig. S1). By contrast, the combination continued to elicit a
stronger antibody and cytotoxic response, and kept 33% of mice free of palpable tumors (Fig. 6)
and alive (Supplementary Fig. S1) at the end of the experiment.
12
At week 20, larger microscopic masses start to become palpable in the mammary pad (Fig.
6). They often display central necrotic areas (Supplementary Fig. S1) since blood vessels are only
present in the surrounding dense and fibrous stroma. These vessels show a diffuse NG2 and alphasmooth muscle actin (markers of nascent and mature pericytes) positivity, which is absent and
scarcely present in the tumor vessels of 16 and 18-week-old mice respectively (Supplementary Fig.
us
its combination with anti-CD25 Ig led to a slightly higher antibody response together with a
e.
S2). At this stage, EC-TM plasmid electroporation elicited only a low antibody response, whereas
substantial cytotoxic response that significantly delayed the appearance of the first palpable tumor
te
r
(Fig. 6) and appreciably reduced both tumor multiplicity (Supplementary Table I) and total tumor
af
burden (Supplementary Fig. S3), though the extension of survival was marginal (Supplementary
Fo
rP
ee
r
R
ev
i
ew
.D
o
no
td
is
t
rib
ut
e.
D
es
tr
oy
Fig. S1).
13
DISCUSSION
BALB-neuT mice are genetically predestined to undergo one of the most aggressive
metastatizing and lethal rErbb2-driven mammary carcinogenesis (11, 12). During the lengthy stepwise progression of their mammary lesions, Treg cells expand to bring about rampant
immunosuppression (19). When the lesions are initial and the tumor-elicited suppression is still
us
e.
negligible, the protection provided by anti-rErbb2 vaccines prevents their progression, and persists
for almost as long as the natural life span of wild-type BALB/c mice (14, 22), whereas their
te
r
efficacy dramatically fades if these initial lesions have progressed, and is almost null against diffuse
af
invasive microscopic tumors (14, 22, 23, 30).
oy
We now report new findings that give insight into the unveiling of latent CD8+ T cell
tr
populations, the therapeutic efficacy stemming from the combination of anti-Erbb2 DNA
D
es
vaccination with anti-CD25 Ig administration, and the limit of this combined treatment in advanced
e.
microscopic tumor stages.
ut
First, in BALB-neuT mice on the threshold of mammary carcinogenesis (10 weeks), two
rib
administration of anti-CD25 Ig lead to a rapid depletion of CD4+ CD25+ GITR+ FoxP3+ Treg cells
is
t
followed by a slow return to the levels of untreated mice. This depletion alone delays the
td
appearance of the first palpable tumor, though all mice have one or more tumor by week 27.
no
Second, the finding that combination of vaccination with anti-CD25 Ig triggers a significant
.D
o
cytotoxic response to the rErrb2 dominant peptide in BALB-neuT mice was unexpected. Our
previous work showed that a significant cytotoxic response was never achieved in BALB-neuT
ew
mice by successful immunizations with vaccines of different kinds (13, 14, 16, 22, 28, 31).
ev
i
Newborn BALB-neuT mice, in fact, express rErbb2 in the thymus and central tolerance appears to
R
delete the CD8+ T clones that interact at high avidity with the dominant H-2Kd Erbb2 peptide in
ee
r
BALB/c mice. Analysis of the TCR repertoire of T cells expanded following anti-rErbb2 DNA
immunization showed that BALB-neuT mice lack these clones, whereas they are expanded in wild-
rP
type BALB/c mice (15).
Fo
Vβ-Jβ spectratyping shows that a low-avidity cytotoxic response is induced by vaccination
plus anti-CD25 Ig; this rests on expansion of CD8+ T cells belonging to an otherwise cryptic TCR
repertoire that do not expand in wild-type BALB/c. In these mice, anti-rErbb2 immunization, alone
or in combination with anti-CD25 Ig, expands only high avidity CD8+ cytotoxic T cells. These data
fit in well with our previous demostration that wild-type BALB/c and transgenic BALB-neuT mice
use distinct and non-overlapping TCR repertoires in response to rErbb2 vaccination (15). Treg cell
depletion does not revert the clonal composition of the CD8+ TCR repertoire specific for the
14
dominat rErbb2 peptide towards that of wild-type BALB/c mice. Instead, it unveils a latent
repertoire of rErbb2-specific CD8+ T cells seemingly exclusive of the BALB-neuT mice. The lowavidity of these cells may underlie their cryptic behavior. While low-avidity cells can escape
thymus selection (10, 32), their access to antigen is possibly limited by competition with T cells of
higher avidity in BALB/c mice (33-35). Alternatively, it can be suggested that the cryptic CD8+
repertoire is positively selected only in BALB-neuT mice as an effect of thymic expression of
us
e.
rErrb2 (15). In these mice, the cryptic repertoire appears to be concealed by Treg cells expanded
following rErbb2 overexpression in the thymus and/or in neoplastic lesions. Reversal of its
te
r
tolerogenic state by Treg cell depletion allows it to expand and display a cytotoxic response. Treg
af
cells also hinder the spontaneous expansion of CD4+ T cells specific for rErbb2. Expansion of the
oy
Vβ11-Jβ2.7 and Vβ13-Jβ2.3 CD4+ T cell repertoires following the administration of anti-CD25 Ig
es
tr
alone suggests that they are naturally present in the periphery of BALB-neuT mice but are
D
suppressed by the expanded Treg cells.
e.
Third, our data also illustrate the importance of counteracting Treg cell expansion in
ut
obtaining a strong antibody response and the induction of a cytotoxic response during cancer
rib
progression, and thus endorse findings in studies of tumors transplanted in syngeneic mice (36) and
is
t
in Erbb2+ tumors transplanted in rErbb2 transgenic mice (5). The inhibitory activity of tumor-
td
expanded Treg cells acts on both CD8+ and CD4+ lymphocytes. Adoptive transfer experiments (22,
no
23) and experiments with BALB-neuT mice rendered deficient in immune components through
.D
o
gene targeting or antibody-mediated depletion of selected lymphocyte populations (16, 22, 23, 28,
31, 37) have made it clear that antibodies elicited by anti-rErbb2 vaccination are both necessary and
ew
sufficient for protection insofar as they impede neoplastic proliferation by directly down-regulating
ev
i
rErbb2 receptor expression, confining it in the cytoplasm and impeding the formation of homo or
R
heterodimers that transduce proliferative signals (16, 28), and triggering cellular cytotoxicity (38).
ee
r
By competing in the binding to antigen presenting cells, Treg cells inhibit the expression of costimulatory molecules (39). Their depletion thus results both in the improved co-stimulatory activity
rP
of antigen presenting cells and in a stronger antibody- and cell-mediated response. The better
Fo
efficacy stemming from the combination of vaccination and anti-CD25 Ig thus rests on both higher
antibody response and activation of the new CD8+ T cell population reacting with low avidity with
rErbb2 that secretes IFNγ and effectively kills p63-71 pulsed cells. In several mouse models, low
avidity T cells alone are enough to suppress the growth of the tumor expressing the antigen (40, 41).
Collaboration of the humoral and the cellular immune responses in rejection of rErbb2 tumors in
transgenic mice has been documented (42). In addition, our previous studies in BALB-neuT mice
receiving the adoptive transfer of antibodies and T cells have shown the importance of both
15
humoral and cellular reactivity in hampering the progression of mammary cancer (22, 24). In
BALB-neuT mice receiving an ErbB-2 vaccine alone, the role of CD8+ T cells in protecting against
rErbB-2 tumors is negligible (13, 17, 28). By contrast, the importance of the cytotoxic activity
appearing after Treg removal, is shown by the fact that depletion of CD8+ T cells reduces the ability
of the combination of vaccine and anti-CD25 Ig to protect BALB-neuT mice from a lethal
challenge of Erbb2+ tumor cells. Moreover, in BALB-neuT mice KO for the μ chain of the Ig and
us
e.
thus unable to produce antibodies following rErbb2 vaccination, the cellular reactivity triggered by
the combined vaccination is enough to delay the progression of Erbb2 mammary lesions, even if it
te
r
does not provide a long lasting protection against the development of autochthonous tumors. This,
af
in fact, requires the presence of anti-Erbb2 antibodies.
oy
The step-wise progression of mammary cancer in BALB-neuT mice has been exploited to
es
tr
show the greater efficacy of vaccination plus Treg cell depletion at tumor stages at which vaccination
alone is ineffective. In mice bearing an atypical hyperplasia in all mammary glands, our anti-
e.
D
rErbb2 DNA vaccine alone doubles the survival time, but by the 65th week of age all mice have
ut
developed tumors. Moreover, while the efficacy of the DNA vaccine alone is no more then
rib
marginal in mice bearing diffuse in situ carcinoma (16th week of age) and early microscopic
is
t
invasive cancer (week 18th), its combination with anti-CD25 Ig was still able to keep a significant
td
number of mice tumor free at week 100, while in those that developed tumors, tumor multiplicity
no
was significantly reduced. This is probably the most significant finding or this study.
.D
o
Fourth, even the more composite and effective immune response induced by the
combination of anti-rErbb2 vaccination with anti-CD25 Ig loses most of its efficacy as the
ew
microscopic lesions progress. Survival, in fact, is no more than marginally extended if this
ev
i
combination is administered when they are nearly palpable in the mammary pad, since it does no
R
more then slowdown the progress of a few lesions and reduce the number of tumors per mouse.
ee
r
This loss of efficacy is probably due to increased resistance acquired by the more advanced
neoplastic lesions as they become more compact and refractory to the immune mechanisms thus
rP
activated (43, 44). The growth of these lesions is fatal, even if the expansion of smaller lesions is
Fo
still controlled by the immune response. However, our data also point to a marked decrease of the
intensity of the immune response elicited by the combination in mice bearing invasive microscopic
cancer. While anti-CD25 Ig still results in Treg cell deletion (data not shown), this interference with
negative regulatory cells is no longer enough to induce a marked antibody response. As a tumor
expands, additional mechanisms such as PGE2-induced, tumor-associated macrophages and IDO
producing dendritic cells (6, 7, 9), may acquire a dominant role in suppressing the immune
response.
16
In conclusion, this study shows that temporary deletion of Treg cells in combination with
anti-rErbb2 vaccination enhances antibody production and activates a latent population of cytotoxic
CD8+ T cells expressing a cryptic repertoire. The immune response thus generated is of therapeutic
significance in that it halts the progression of lesions that cannot be inhibited by vaccination alone.
These results underscore the importance of using optimal vaccine strategy when targeting tumor
antigens (5, 45). However, our data also indicate that caution is needed when assessing the
us
e.
significance of vaccination plus Treg cell deletion in a clinical setting, since it is quite possible that
the long-lasting tumor host relationship that characterize human tumors will minimize the immune
te
r
advantage due to such depletion unaccompanied by attempts to counter other forms of immune
af
suppression. Moreover, even though BALB-neuT mice reproduce several features of human breast
oy
cancer, one cannot rule out the possibility that the different patterns and timing of transgene
ut
e.
D
es
tr
expression lead to an immune tolerance to Erbb2 different from that of tumor patients (1).
rib
Acknowledgments
Fo
rP
ee
r
R
ev
i
ew
.D
o
no
td
is
t
We thank Prof. John Iliffe for editing the manuscript.
17
Footnotes
This study was funded under the auspices of EUCAAD 200755. The project EUCAAD has received
research funding from the European Community's Seventh Framework Programme. This work was
also supported by grants from Italian Association for Cancer Research; the Italian Ministero
dell’Università e della Ricerca; the University of Torino; the Compagnia di San Paolo, Torino; the
us
e.
Fondazione Denegri, Torino; the Fondazione Internazionale di Ricerca in Medicina Sperimentale
af
Centre of Excellence for development of anti tumor Vaccine concepts (NCEV).
te
r
(FIRMS), Torino; the Fondazione CRT, progetto Alfieri; the Regione Piemonte; and the Nordic
oy
Abbreviations used in this paper: rErbb2, rat Erbb2; BALB-neuT mice, rErbb2 transgenic
tr
BALB/c mice; Treg cell, T regulatory cell; EC-TM, extracellular and trans-membrane domains
D
es
of the protein product of rErbb2; LN, lymph node; SPC, spleen cell suspension; RSI, rate of
Fo
rP
ee
r
R
ev
i
ew
.D
o
no
td
is
t
rib
ut
e.
Stimulation Index; V, variable; J, joining; CDR, complementarity-determining region.
18
LEGENDS TO FIGURES:
FIGURE 1. Sustained depletion of CD4+ CD25+ GITR+ FoxP3+ Treg cells in tumor draining
LN of BALB-neuT mice following anti-CD25 Ig administration. At the 10th week of age,
e.
BALB-neuT mice with diffuse preneoplastic lesions in all mammary glands receive an injection of
te
r
with the EC-TM plasmid on the first day of week 10 and 12 (■), while other mice were
us
500 μg of anti-CD25 Ig (○) or control rat Ig (◊) on day 2 and 5. Other mice were electroporated
af
electroporated with the EC-TM plasmid and injected anti-CD25 Ig (●). At each time points, the
oy
percentage of CD4+ CD25+ GITR+ FoxP3+ cells was evaluated individually in groups of 6 mice.
es
tr
The mean value and range (vertical bars) are shown.
D
FIGURE 2. The combination of EC-TM plasmid electroporation with anti-CD25 Ig
e.
administration enhances tumor free survival and induces a persistent antibody and low
rib
ut
avidity cytotoxic response. At the 10th week of age, groups of BALB-neuT mice with diffuse
is
t
preneoplastic lesions in all mammary glands receive an injection of 500 μg of anti-CD25 Ig (○, 22
td
mice) on day 2 and 5. Other mice were electroporated on the first day of week 10 and 12 with the
empty (◊, 22 mice) or EC-TM plasmid (■, 20 mice), while other mice were electroporated with the
no
EC-TM plasmid and injected with anti-CD25 Ig (●, 29 mice). Mice of the same age were randomly
.D
o
assigned to the concurrently treated control and experimental groups. Each experiment was repeated
ew
two to four times, and the results were cumulated. Panel A: Tumor incidence in mice receiving ECTM plasmid electroporation combined with anti-CD25 Ig is significantly different (P < 0.0001) as
ev
i
compared with all other groups. Tumor incidence was significantly delayed in mice injected with
R
anti-CD25 Ig alone (p<0.0001), electroporated with EC-TM plasmid and injected with anti-CD25
ee
r
Ig (p<0.0001) as compared to untreated mice (not shown) or mice electroporated with the empty
rP
pcDNA3 plasmid. Tumor incidence in groups of 10 mice untreated and electroporated with empty
Fo
pcDNA3 plasmid combined with the two infusions of anti-CD25 Ig were not significantly different
from that in mice injected with anti-CD25 Ig alone, and the data are not shown. Panel B:
Development of the titer of anti-rErbb2 antibodies evaluated in individual mice. Horizontal lines:
titer mean. Panel C: Development of cytotoxic in vivo response against dominant p63-71 rErbb2
peptide. Horizontal lines: geometric mean. Only mice that were still tumor-free were tested.
19
FIGURE 3. Dominat rErbb2 peptide T cell repertoires triggered by EC-TM plasmid
electroporation and anti-CD25 Ig administration in BALB-neuT mice. Panel A: Complete
CDR3-β immunoscope analysis of the immune response to p63-71 peptide in a pool of 5 BALBneuT mice. Mice were electroporated on week 10 and 12 with EC-TM plasmid and injected with
anti-CD25 Ig one and four days after the first electroporation. Their popliteal and inguinal LN cells
were re-stimulated in vitro with the immunodominant rErbb2 peptide p63-71. cDNA were
us
e.
amplified by PCR with a combination of all 24 V primers and a common C primer; after a run-off
reaction with 12 J fluorescent primers, products were analyzed in a DNA sequencer. Filled squares
te
r
indicate V-J rearrangements showing p63-71 specific expansion. Panel B: Frequencies of the
af
specific p63-71 peptide repertoires in 10 individual mice electroporated and treated with anti-CD25
oy
Ig as in (A). Each column shows one mouse and filled squares indicate rearrangements used by
tr
individual mice. Frequencies of usage of the rearrangements are indicated as number of mice that
e.
D
es
use that recombination/total mice.
ut
FIGURE 4. p63-71 specific T cells are elicited by the combined treatment. Features of the T cell
rib
reactivity elicited in BALB/c, BALB-neuT and BALB-neuT/BKO mice electroporated on week 10
is
t
and 12 with EC-TM plasmid and injected or not with anti-CD25, tested on week 14. Panel A: In
td
vivo citotoxicity against cells pulsed with 3 or 15 µM p63-71. Empty bars: BALB/c mice
no
electroporated with EC-TM only; black bars: BALB-neuT mice electroporated with EC-TM and
.D
o
injected with anti-CD25. A representative experiment of three performed independently is shown.
Panel B: Staining of CD8+ cells (in purple) close to mammary ducts in BALB-neuT mice
ew
electroporated with EC-TM only (left panel) and those receiving the combined treatment (right
ev
i
panel) (x40). CD8+ cells infiltrating mammary glands counted around 40 ducts per group were: 1.65
R
± 0.9 (mean ± SD) in mice receiving the combination treatment, and 0.68 ± 0.28 in those
ee
r
electroporated with EC-TM only (p < 0.0001. Panel C: Tumor incidence in BALB-neuT/BKO mice
rP
untreated (5 mice) and receiving the combined treatment (4 mice).
Fo
FIGURE 5. p63-71 specific T cells are of low-avidity. Panel A: IFNγ production by CD8+ LN
cells restimulated with 3, 15 and 50 µM p63-71. Mean ± SD of the number of positive cells /105
cells. (○) BALB/c mice electroporated with EC-TM on week 10 and 12; (●) BALB-neuT mice
electroporated with EC-TM at week 10 and 12 and injected with anti-CD25 Ig. CD8+ LN cells
were tested on week 14. Horizontal lines: means. Statistic compares BALB-neuT versus BALB/c.
Panel B: RSI of shared TCR rearrangements used by CD8+ LN cells of BALB-neuT (Vβ1-Jβ1.1,
Vβ6-Jβ2.7, Vβ7-Jβ1.2 ) and BALB/c mice (Vβ9-Jβ1.2) restimulated at the same concentration of
20
p63-71 as above and by T cells infiltrating mammary lesions. Results are indicated as average RSI,
where RSI of 1 indicates no stimulation.
FIGURE 6. Anti-CD25 enhances the therapeutic activity of EC-TM electroporation in BALBneuT mice. At progressive stages of mammary carcinogenesis, BALB-neuT mice received EC-TM
us
electroporation course. The pictures in the left panel show mammary gland whole mount
e.
electroporation alone or combined with anti-CD25 Ig injected 14 and 10 days before the
preparations performed in unvaccinated mice at 16, 18 and 20 weeks of age. At 16 weeks the
te
r
mammary gland displays multiple small opacities surrounding the mammary ducts indicating the
af
presence of diffuse atypical hyperplastic lesions and several foci of in situ carcinoma. At 18 weeks
oy
several discrete dark nodules corresponding to in situ and early invasive carcinomas are present
tr
while the larger nodules with irregular borders present at 20 weeks are interpretable as solid
Fo
rP
ee
r
R
ev
i
ew
.D
o
no
td
is
t
rib
ut
e.
D
es
invasive carcinomas. The central oval black areas are mammary LN. Magnification x 6.3.
21
References
2.
3.
tr
rib
ee
r
Fo
13.
rP
12.
R
ev
i
11.
ew
10.
.D
o
no
td
9.
is
t
8.
ut
e.
7.
D
es
6.
oy
af
5.
te
r
us
4.
Lollini, P. L., F. Cavallo, P. Nanni, and G. Forni. 2006. Vaccines for tumour prevention. Nat
Rev Cancer 6:204-216.
Shevach, E. M. 2002. CD4+ CD25+ suppressor T cells: more questions than answers. Nat
Rev Immunol 2:389-400.
Dunn, G. P., L. J. Old, and R. D. Schreiber. 2004. The immunobiology of cancer
immunosurveillance and immunoediting. Immunity 21:137-148.
Ko, K., S. Yamazaki, K. Nakamura, T. Nishioka, K. Hirota, T. Yamaguchi, J. Shimizu, T.
Nomura, T. Chiba, and S. Sakaguchi. 2005. Treatment of advanced tumors with agonistic
anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.
J Exp Med 202:885-891.
Ercolini, A. M., B. H. Ladle, E. A. Manning, L. W. Pfannenstiel, T. D. Armstrong, J. P.
Machiels, J. G. Bieler, L. A. Emens, R. T. Reilly, and E. M. Jaffee. 2005. Recruitment of
latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med
201:1591-1602.
Sica, A., T. Schioppa, A. Mantovani, and P. Allavena. 2006. Tumour-associated
macrophages are a distinct M2 polarised population promoting tumour progression:
potential targets of anti-cancer therapy. Eur J Cancer 42:717-727.
Sinha, P., V. K. Clements, A. M. Fulton, and S. Ostrand-Rosenberg. 2007. Prostaglandin E2
promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res
67:4507-4513.
Zou, W. 2005. Immunosuppressive networks in the tumour environment and their
therapeutic relevance. Nat Rev Cancer 5:263-274.
von Bergwelt-Baildon, M. S., A. Popov, T. Saric, J. Chemnitz, S. Classen, M. S. Stoffel, F.
Fiore, U. Roth, M. Beyer, S. Debey, C. Wickenhauser, F. G. Hanisch, and J. L. Schultze.
2006. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and
expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell
inhibition. Blood 108:228-237.
Zou, W. 2006. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol
6:295-307.
Boggio, K., G. Nicoletti, E. Di Carlo, F. Cavallo, L. Landuzzi, C. Melani, M. Giovarelli, I.
Rossi, P. Nanni, C. De Giovanni, P. Bouchard, S. Wolf, A. Modesti, P. Musiani, P. L.
Lollini, M. P. Colombo, and G. Forni. 1998. Interleukin 12-mediated prevention of
spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp
Med 188:589-596.
Husemann, Y., J. B. Geigl, F. Schubert, P. Musiani, M. Meyer, E. Burghart, G. Forni, R.
Eils, T. Fehm, G. Riethmuller, and C. A. Klein. 2008. Systemic spread is an early step in
breast cancer. Cancer Cell 13:58-68.
Rovero, S., A. Amici, E. D. Carlo, R. Bei, P. Nanni, E. Quaglino, P. Porcedda, K. Boggio,
A. Smorlesi, P. L. Lollini, L. Landuzzi, M. P. Colombo, M. Giovarelli, P. Musiani, and G.
Forni. 2000. DNA vaccination against rat her-2/Neu p185 more effectively inhibits
carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol
165:5133-5142.
Nanni, P., G. Nicoletti, C. De Giovanni, L. Landuzzi, E. Di Carlo, F. Cavallo, S. M. Pupa, I.
Rossi, M. P. Colombo, C. Ricci, A. Astolfi, P. Musiani, G. Forni, and P. L. Lollini. 2001.
Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary
carcinogenesis in HER-2/neu transgenic mice. J Exp Med 194:1195-1205.
e.
1.
14.
22
15.
16.
D
rib
no
.D
o
ee
r
Fo
26.
rP
25.
R
ev
i
24.
ew
23.
td
is
t
22.
ut
e.
21.
es
tr
20.
oy
af
19.
te
r
18.
us
e.
17.
Rolla, S., C. Nicolo, S. Malinarich, M. Orsini, G. Forni, F. Cavallo, and F. Ria. 2006.
Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in
wild-type and HER-2 transgenic BALB/c mice. J Immunol 177:7626-7633.
Quaglino, E., S. Rolla, M. Iezzi, M. Spadaro, P. Musiani, C. De Giovanni, P. L. Lollini, S.
Lanzardo, G. Forni, R. Sanges, S. Crispi, P. De Luca, R. Calogero, and F. Cavallo. 2004.
Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu
preneoplastic lesions. J Clin Invest 113:709-717.
Nanni, P., L. Landuzzi, G. Nicoletti, C. De Giovanni, I. Rossi, S. Croci, A. Astolfi, M. Iezzi,
E. Di Carlo, P. Musiani, G. Forni, and P. L. Lollini. 2004. Immunoprevention of mammary
carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent. J Immunol
173:2288-2296.
Pannellini, T., G. Forni, and P. Musiani. 2004. Immunobiology of her-2/neu transgenic
mice. Breast Dis 20:33-42.
Ambrosino, E., M. Spadaro, M. Iezzi, C. Curcio, G. Forni, P. Musiani, W. Z. Wei, and F.
Cavallo. 2006. Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed
by a dominant regulatory T-cell self-tolerance. Cancer Res 66:7734-7740.
Melani, C., C. Chiodoni, G. Forni, and M. P. Colombo. 2003. Myeloid cell expansion
elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic
BALB/c mice suppresses immune reactivity. Blood 102:2138-2145.
Park, J. M., M. Terabe, D. D. Donaldson, G. Forni, and J. A. Berzofsky. 2008. Natural
immunosurveillance against spontaneous, autochthonous breast cancers revealed and
enhanced by blockade of IL-13-mediated negative regulation. Cancer Immunol Immunother
57:907-912.
Quaglino, E., M. Iezzi, C. Mastini, A. Amici, F. Pericle, E. Di Carlo, S. M. Pupa, C. De
Giovanni, M. Spadaro, C. Curcio, P. L. Lollini, P. Musiani, G. Forni, and F. Cavallo. 2004.
Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu
transgenic mice. Cancer Res 64:2858-2864.
Spadaro, M., E. Ambrosino, M. Iezzi, E. Di Carlo, P. Sacchetti, C. Curcio, A. Amici, W. Z.
Wei, P. Musiani, P. L. Lollini, F. Cavallo, and G. Forni. 2005. Cure of mammary
carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant
interleukin-12) and adaptive (DNA vaccine electroporation) immunity. Clin Cancer Res
11:1941-1952.
Rolla, S., C. Marchini, S. Malinarich, E. Quaglino, S. Lanzardo, M. Montani, M. Iezzi, M.
Angeletti, G. Ramadori, G. Forni, F. Cavallo, and A. Amici. 2008. Protective immunity
against neu-positive carcinomas elicited by electroporation of plasmids encoding decreasing
fragments of rat neu extracellular domain. Hum Gene Ther 19:229-240.
Ritchie, D. S., I. F. Hermans, J. M. Lumsden, C. B. Scanga, J. M. Roberts, J. Yang, R. A.
Kemp, and F. Ronchese. 2000. Dendritic cell elimination as an assay of cytotoxic T
lymphocyte activity in vivo. J Immunol Methods 246:109-117.
Nagata, Y., R. Furugen, A. Hiasa, H. Ikeda, N. Ohta, K. Furukawa, H. Nakamura, T.
Kanematsu, and H. Shiku. 1997. Peptides derived from a wild-type murine proto-oncogene
c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol
159:1336-1343.
Ria, F., A. Gallard, C. R. Gabaglia, J. C. Guery, E. E. Sercarz, and L. Adorini. 2004.
Selection of similar naive T cell repertoires but induction of distinct T cell responses by
native and modified antigen. J Immunol 172:3447-3453.
Park, J. M., M. Terabe, Y. Sakai, J. Munasinghe, G. Forni, J. C. Morris, and J. A. Berzofsky.
2005. Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection
against autochthonous mammary carcinomas. J Immunol 174:4228-4236.
Fasso, M., N. Anandasabapathy, F. Crawford, J. Kappler, C. G. Fathman, and W. M.
Ridgway. 2000. T cell receptor (TCR)-mediated repertoire selection and loss of TCR vbeta
27.
28.
29.
23
34.
40.
e.
us
te
r
ut
td
no
Fo
43.
rP
ee
r
42.
R
ev
i
41.
.D
o
39.
ew
38.
is
t
rib
37.
e.
D
35.
36.
af
33.
oy
32.
tr
31.
es
30.
diversity during the initiation of a CD4(+) T cell response in vivo. J Exp Med 192:17191730.
Curcio, C., A. S. Khan, A. Amici, M. Spadaro, E. Quaglino, F. Cavallo, G. Forni, and R.
Draghia-Akli. 2007. DNA immunization using constant-current electroporation affords
long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic
mice. Cancer Gene Ther.
Sakai, Y., B. J. Morrison, J. D. Burke, J. M. Park, M. Terabe, J. E. Janik, G. Forni, J. A.
Berzofsky, and J. C. Morris. 2004. Vaccination by genetically modified dendritic cells
expressing a truncated neu oncogene prevents development of breast cancer in transgenic
mice. Cancer Res 64:8022-8028.
McMahan, R. H., and J. E. Slansky. 2007. Mobilizing the low-avidity T cell repertoire to
kill tumors. Semin Cancer Biol 17:317-329.
Kedl, R. M., W. A. Rees, D. A. Hildeman, B. Schaefer, T. Mitchell, J. Kappler, and P.
Marrack. 2000. T cells compete for access to antigen-bearing antigen-presenting cells. J Exp
Med 192:1105-1113.
Block, M. S., M. J. Hansen, V. P. Van Keulen, and L. R. Pease. 2003. MHC class I gene
conversion mutations alter the CD8 T cell repertoire. J Immunol 171:4006-4010.
Lanzavecchia, A. 2002. Lack of fair play in the T cell response. Nat Immunol 3:9-10.
Jacob, J. B., Y. C. Kong, C. Meroueh, D. P. Snower, C. S. David, Y. S. Ho, and W. Z. Wei.
2007. Control of Her-2 tumor immunity and thyroid autoimmunity by MHC and regulatory
T cells. Cancer Res 67:7020-7027.
Cappello, P., F. Triebel, M. Iezzi, C. Caorsi, E. Quaglino, P. L. Lollini, A. Amici, E. Di
Carlo, P. Musiani, M. Giovarelli, and G. Forni. 2003. LAG-3 enables DNA vaccination to
persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice.
Cancer Res 63:2518-2525.
Cavallo, F., R. Offringa, S. H. van der Burg, G. Forni, and C. J. Melief. 2006. Vaccination
for treatment and prevention of cancer in animal models. Adv Immunol 90:175-213.
Wing, K., Y. Onishi, P. Prieto-Martin, T. Yamaguchi, M. Miyara, Z. Fehervari, T. Nomura,
and S. Sakaguchi. 2008. CTLA-4 control over Foxp3+ regulatory T cell function. Science
322:271-275.
Lustgarten, J., A. L. Dominguez, and C. Pinilla. 2006. Identification of cross-reactive
peptides using combinatorial libraries circumvents tolerance against Her-2/neuimmunodominant epitope. J Immunol 176:1796-1805.
Morgan, D. J., H. T. Kreuwel, S. Fleck, H. I. Levitsky, D. M. Pardoll, and L. A. Sherman.
1998. Activation of low avidity CTL specific for a self epitope results in tumor rejection but
not autoimmunity. J Immunol 160:643-651.
Kim, P. S., T. D. Armstrong, H. Song, M. E. Wolpoe, V. Weiss, E. A. Manning, L. Q.
Huang, S. Murata, G. Sgouros, L. A. Emens, R. T. Reilly, and E. M. Jaffee. 2008. Antibody
association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice
through Fc-mediated activation of DCs. J Clin Invest 118:1700-1711.
Jain, R. K. 2001. Delivery of molecular and cellular medicine to solid tumors. Adv Drug
Deliv Rev 46:149-168.
Gade, T. P., I. M. Buchanan, M. W. Motley, Y. Mazaheri, W. M. Spees, and J. A. Koutcher.
2009. Imaging intratumoral convection: pressure-dependent enhancement in
chemotherapeutic delivery to solid tumors. Clin Cancer Res 15:247-255.
Antony, P. A., C. A. Piccirillo, A. Akpinarli, S. E. Finkelstein, P. J. Speiss, D. R. Surman,
D. C. Palmer, C. C. Chan, C. A. Klebanoff, W. W. Overwijk, S. A. Rosenberg, and N. P.
Restifo. 2005. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T
helper cells and hindered by naturally occurring T regulatory cells. J Immunol 174:25912601.
44.
45.
24
Table I: Usage of T cell repertoire rearrangements in BALB/c and BALB-neuT mice electroporated
with EC-TM plasmid and/or treated with anti-CD25 Ig
Mice
Treatment
Vβ6-Jβ2.7a
Vβ1-Jβ1.1 a
Vβ7-Jβ1.2 a
Vβ9-Jβ1.2 a
Vβ11-Jβ2.7b
BALB/c
EC-TM
anti-CD25Ig
EC-TM+ anti-CD25Ig
0/5c (0%)
0/5 (0%)
0/5 (0%)
0/5 (0%)
0/5 (0%)
0/5 (0%)
0/5 (0%)
0/5 (0%)
0/5 (0%)
5/5 (100%)
0/5 (0%)
5/5 (100%)
0/5 (0%)
0/5 (0%)
0/5 (0%)
0/5 (0%)
3/8 (38%)
9/14 (64%)
0/5 (0%)
3/8 (38%)
7/14 (50%)
0/5
4/8 (50%)
9/14 (64%)
0/5 (0%)
0/8 (0%)
0/14 (0%)
5/5 (100%)
2/4 (50%)
14/14 (100%)
e.
us
te
r
af
0/5 (0%)
0/5 (0%)
0/5 (0%)
5/5 (100%)
1/4 (25%)
14/14 (100%)
tr
oy
BALB-neuT EC-TM
anti-CD25Ig
EC-TM+anti-CD25Ig
b
Vβ13-Jβ2.3 b
a
es
TCR rearrangements expanded following p63-71 Erbb2 peptide in vitro restimulation
TCR rearrangements expanded in lymph node cells from variously treated mice recovered after in vitro re-stimulation
with rErbb2+ 3T3-NKB cells.
c
Mice using the indicated TCR rearrangement/number of total analyzed mice
Fo
rP
ee
r
R
ev
i
ew
.D
o
no
td
is
t
rib
ut
e.
D
b
Fo
o rP
no ee
tr t d r R
oy i e
af stri vie
te bu
r u te
se .
.
Fo
D r
D o n Pe
es o e
tr t d r R
oy i e
af stri vie
te bu w
r u te .
se .
.
ib
ut
rR
D e
es vi
tr ew
oy .
af Do
te n
r u ot
se di
. str
ee
rP
Fo
e.
Fo
D r
D o n Pe
es o e
tr t d r R
oy i e
af stri vie
te bu w
r u te .
se .
.
Fo
D r
D o n Pe
es o e
tr t d r R
oy i e
af stri vie
te bu w
r u te .
se .
.
e.
ib
ut
rR
D e
es vi
tr ew
oy .
af Do
te n
r u ot
se di
. str
ee
rP
Fo